0
Politics
Double Downgrade: Abbott India Share Price Target, Rating Slashed On Weak Growth Outlook
April 15, 2026
Scroll
Posted 2 hours ago by
Competitive pressures, particularly from global players like Novo Nordisk, are intensifying, especially with the transition toward next-generation diabetes therapies, like GLP-1.
NDTV
Coverage and analysis from India. All insights are generated by our AI narrative analysis engine.
India
Bias: lean right
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.